Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? by Ueno, H et al.
Minireview
Pharmacogenomics of gemcitabine: can genetic studies lead to
tailor-made therapy?
H Ueno*,1, K Kiyosawa
2 and N Kaniwa
3
1Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan;
2Oncology Business
Unit, Eli Lilly Japan KK, 1-1-1, Shin Aoyama Bldg. West 22F, 1-1-1, Minami-Aoyama, Minato-ku, Tokyo 107-0062, Japan;
3Division of Medicinal Safety
Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan
Gemcitabine is a deoxycytidine analogue that has a broad spectrum of antitumour activity in many solid tumours including pancreatic
cancer. We have recently carried out a pharmacogenomic study in cancer patients treated with gemcitabine, and found that one
genetic polymorphism of an enzyme involved in gemcitabine metabolism can cause interindividual variations in the pharmacokinetics
and toxicity of this agent. In this paper, we review recent genetic studies of gemcitabine, and discuss the possibility of individualised
cancer chemotherapy based on a pharmacogenomic approach.
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With progress in the development of anticancer agents, many
cancer patients now benefit from chemotherapy. Before treatment,
however, it is difficult to predict whether the selected chemo-
therapy will be really effective and tolerable to the patient. Therefore,
considerable effort has been made to obtain information that could
be used to devise tailor-made therapy. Recent progress in
molecular biology has revealed that genetic factors can at least
partly explain interindividual variations in the efficacy and toxicity
of anticancer agents. We have recently carried out a prospective
pharmacogenomic study in cancer patients treated with gemcita-
bine (20,20-difluorodeoxycytidine, dFdC), and found that one of the
single-nucleotide polymorphisms (SNPs) in the cytidine deami-
nase gene influences the pharmacokinetics and toxicities of this
agent (Sugiyama et al, 2007). Gemcitabine is a deoxycytidine
analogue that demonstrates broad anticancer activity in various
solid tumours, including pancreatic cancer and non-small-cell lung
cancer (NSCLC). Because of the widespread use of gemcitabine, a
better understanding of the mechanisms determining its activa-
tion, and development of resistance against it has been needed,
and this has prompted active genetic studies in relation to this
agent. In this review, therefore, we focus on genetic studies of
gemcitabine that have yielded data potentially useful for the
establishment of individualised cancer chemotherapy.
GEMCITABINE METABOLISM AND MECHANISM
OF ACTION
Like cytarabine, another widely used nucleoside analogue, gemci-
tabine is a prodrug that requires cellular uptake and intracellular
phosphorylation in order to exert its action (Figure 1) (Fukunaga
et al, 2004; Mini et al, 2006). Once administered, gemcitabine is
transported into cells by nucleoside transporters. Gemcitabine is
then phosphorylated into gemcitabine monophosphate (dFdCMP)
by deoxycytidine kinase (DCK), and dFdCMP is subsequently
phosphorylated to gemcitabine diphosphate (dFdCDP) and gemci-
tabine triphosphate (dFdCTP) by nucleoside monophosphate
(UMP/CMP) and diphosphate kinase. Gemcitabine exerts its
cytotoxic effect mainly through inhibition of DNA synthesis by
being incorporated into the DNA strand as the active dFdCTP. It is
known that gemcitabine has a unique mechanism of action known
as ‘self-potentiation’ (Heinemann et al, 1992). For example, dFdCDP
potently inhibits ribonucleotide reductase, resulting in a decrease of
competing deoxyribonucleotide pools necessary for DNA synthesis.
Again, dFdCTP suppresses inactivation of dFdCMP by inhibiting
deoxycytidine monophosphate deaminase (DCTD). On the other
hand, more than 90% of administered gemcitabine is converted, and
thus inactivated, by cytidine deaminase (CDA) into 20-deoxy-20,20-
difluorouridine (dFdU). Phosphorylated metabolites of gemcitabine
are reduced by cellular 50-nucleotidase (50-NT), and dFdCMP is also
converted, and inactivated, by DCTD into 20-deoxy-20,20-difluoro-
uridine monophosphate (dFdUMP).
This paper discusses these various metabolic pathways related to
gemcitabine cellular pharmacology and DNA repair. In Table 1, we
summarise the genetic polymorphisms related to gemcitabine
pathways, their allele frequencies in different ethnic groups, and
the resulting functional changes. In this paper, A of the translation
initiation codon ATG is numbered 1 and the first methionine of a
protein is numbered 1.
NUCLEOSIDE TRANSPORTERS
Gemcitabine is transported into cells by five nucleoside transpor-
ters, two equilibrative nucleoside transporters (ENTs; ENT1
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www.bjcancer.com(SLC29A1) and ENT2 (SLC29A2)) and three concentrative
nucleoside transporters (CNTs; CNT1 (SLC28A1), CNT2
(SLC28A2), and CNT3 (SLC28A3)) (Mini et al, 2006). Kinetic
studies of human cell lines have shown that gemcitabine
intracellular uptake is mediated mainly by ENT1 and, to a lesser
extent, by CNT1 and CNT3.
The reported allele frequencies of nucleoside transporter gene
variants are generally low except ENT1  706 G4C in Caucasians
and ENT1  1050 G4A in Africans, as shown in Table 1 (Osato
et al, 2003; Damaraju et al, 2005; Kim et al, 2006; Myers et al,
2006). To date, it is unclear whether these genetic variants of
nucleoside transporter genes including ENT1 contribute to
interindividual differences in response to gemcitabine. The
functional analyses of the two nonsynonymous SNPs of ENT1
(SLC29A1 647T4C and 1171G4A) and the three nonsynonymous
SNPs of CNT3 (SLC28A3 14G4A, 391 C4T, and 1538A4T) failed
to demonstrate functional diversity (Osato et al, 2003; Damaraju
et al, 2005). On the other hand, a recent study found that
individuals with CGG/CGC haplotypes based on the three SNPs in
the promoter region of ENT1 (SLC29A1  1345C4G,  1050 G4A,
 706G4C) showed 1.37-fold higher median expression of the
ENT1 transcript than those with the common CGG/CGG
haplotypes, suggesting that ENT1 promoter region variants may
influence gene expression and alter gemcitabine chemosensitivity
(Myers et al, 2006).
As to expression, several studies have suggested that
ENT1 expression of mRNA/proteins in tumour tissues may be a
good predictive marker of outcome in cancer patients receiving
gemcitabine. Spratlin et al (2004) performed an immunohisto-
chemical study on paraffin-embedded tumour tissues from
21 patients with pancreatic cancer and reported that overall
survival was significantly longer in those expressing detectable
amounts of ENT1 in tumour blocks than in those with low or
absent ENT1 following gemcitabine treatment (median, 13 months
vs 4 months; P¼0.01). Polymerase chain reaction analysis
of 81 patients with pancreatic cancer also showed that those
with high ENT1 mRNA expression in the tumour specimens
had significantly longer survival after gemcitabine therapy than
patients with low ENT1 levels (median, 25.7 vs 8.5 months;
Po0.001) (Giovannetti et al, 2006). Similar results were obtained
in a study of 12 bladder cancer patients treated with gemcitabine,
which demonstrated that the mean level of ENT1 mRNA in
tumour specimens was significantly higher in patients achieving
a complete pathological response than in those with stable
disease (1.166 vs 1.021; P¼0.040) (Mey et al, 2006). These results
suggest that tumour-specific expression of ENT1 may be a
promising predictive biomarker of outcome after gemcitabine
treatment, although formal validation in prospective studies is
needed.
CYTIDINE DEAMINASE
Cytidine deaminase is involved in the salvaging of pyrimidines,
and plays a key role in detoxifying gemcitabine. Therefore, patients
with impaired CDA activity might develop strong toxicities after
administration of gemcitabine, while CDA overexpression in
tumour tissues might reduce the antitumour efficacy of this drug.
An in vitro study has demonstrated resistance to gemcitabine in
cells overexpressing CDA (Neff and Blau, 1996).
So far, two nonsynonymous SNPs, 79A4C (Lys27Gln) and
208G4A (Ala70Thr), have been identified in the coding region
of the human CDA gene (Yue et al, 2003; Fukunaga et al, 2004;
Gilbert et al, 2006; Sugiyama et al, 2007). Ethnic or
racial differences in the allele frequencies of these SNPs have
been reported, as shown in Table 1. Remarkable reduction in
activity of 70Thr CDA was reported in vitro (Yue et al, 2003)
and in vivo (Sugiyama et al, 2007), while only marginal reduction
in activity of 27Gln CDA was observed in vitro (Yue et al, 2003;
Gilbert et al, 2006). On the other hand, Fitzgerald et al (2006)
investigated SNPs in the promoter region of CDA in vitro and in
vivo, and found that some promoter CDA haplotypes might affect
CDA activity.
With regard to the correlation between CDA SNPs and
clinical outcome, we have recently carried out a prospective
pharmacogenomic study in cancer patients treated with
gemcitabine (Sugiyama et al, 2007). In that study, 256 Japanese
patients who had not previously received gemcitabine were
enrolled. In our study, we defined the haplotype without
amino-acid changes as the *1 group, and haplotypes harbouring
the 79A4C and 208G4A were designated *2 and *3, respectively.
The relationships between the diplotype groups and the pharma-
cokinetic parameters of gemcitabine are summarised in Table 2.
The data clearly showed a haplotype *3-dependent decrease in
gemcitabine clearance (CLm
 2) and increases in peak concentra-
tion (Cmax) and area under the curve (AUC) values, although
these parameters were not significantly influenced by haplotype *2.
The values of AUC and CLm
 2 observed in the patient with
208AA (*3/*3) were five-fold and one-fifth of the median
of the 208GG (non*3/non*3) group, respectively (Figure 2). Then,
associations of haplotype *3 with toxicities were analysed.
Nadir grades of neutrophil counts were compared between the
patient groups with or without haplotype *3 under individual
therapeutic regimens. Although there were no significant
differences in the incidences of grade X3 neutropaenia between
the two groups receiving gemcitabine monotherapy, grade X3
neutropaenia occurred more frequently in the group with
haplotype *3 than in the group without haplotype*3
when gemcitabine was administered with carboplatin, cisplatin,
or 5-fluorouracil. We concluded that haplotype *3 harbouring
208G4A decreased the clearance of gemcitabine, and
increased the incidence of neutropaenia when patients
were coadministered platinum-containing drugs or 5-fluorouracil.
Indeed, the patient with CDA 208AA developed severe myelosup-
pression with severe gastrointestinal toxicities after gemcitabine
plus cisplatin combination therapy (Yonemori et al, 2005).
Extra caution may be necessary if patients carrying a *3
allele, especially those who are homozygous for *3, are
treated with gemcitabine. On the other hand, Vasile et al
(2006) recently examined the correlation between CDA SNPs and
clinical efficacy in 61 NSCLC patients treated with gemcitabine
alone or gemcitabine plus cisplatin, and reported that the
patients with CDA 79AA (n¼21) showed a significantly better
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Figure 1 Cellular metabolism and mechanism of gemcitabine. For
explanation of symbols and metabolic routes, see text.
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79AC or 79CC (n¼40) (response rate: 52.4 vs 20%; median
progression-free survival: 8.0 vs 2.5 months; P¼0.0136). Further
functional and clinical studies focusing on these CDA SNPs are
required.
With regard to gene expression, Ganti et al (2006) investigated
the gene expression of CDA in bone marrow mononuclear
cells in 71 patients with advanced solid tumours, and reported
that patients with a lower relative gene expression of CDA
tended to show a higher incidence of grades 2–4 haematological
toxicity during gemcitabine therapy. Recently, some additional
interesting results have been reported by Bengala et al (2005),
who performed a phase I study of gemcitabine infusion at a
fixed dose rate in patients with pancreatic cancer, and also
investigated the relationship between CDA mRNA expression in
peripheral blood mononuclear cells and clinical outcome.
They reported that patients with a lower gene expression
level of CDA showed significant longer overall survival than
those with a higher expression level (median, 8.5 vs 3.7 months;
P¼0.03). On the other hand, as to expression in tumour
tissues, Giovannetti et al (2006) reported that multivariate
analysis failed to show any prognostic significance of CDA mRNA
expression in 81 patients with pancreatic cancer receiving
gemcitabine.
Table 1 Reported SNPs of genes involved in the gemcitabine pathways and their allele frequencies in three ethnic groups
Allele frequencies
Gene
Variant
nucleotide
location
a
Amino-acid
change
b Functional study Africans Ref. Caucasians Ref. Asians Ref.
ENT1 (SLC29A1)
(NT_007592.14)
 1345 C4G Different mRNA
expression among
haplotypes
1
0.08 1 0 1 0.002 2
 1050 G4A 0.19 1 0 1 0 2
 706 G4C 0.05 1 0.21 1 0 2
177 C4G Asp59Glu 0.002 2
647 T4C Ile216Thr No functional
change
3
0.005 3 0.021 3 0 2, 3
1171 G4A Glu391Lys No functional
change
3
0.01 3 0 3 0 2, 3
1288 G4A Ala430Thr 0.002 2
CNT3 (SLC28A3)
(NT_023935.17)
14 G4A Ser5Asn No functional
change
4
0.01 4
391 C4T
c Leu131Phe No functional
change
4
0.01 4
1538 A4T Try513Phe No functional
change
4
0.06 4
CDA (NT_004610.18)  897 C4A Different activity
among haplotypes
5
0.02 (ethnic group unknown) 5
 451 C4T 0.26 (ethnic group unknown) 5 0.199 6
 92 A4G 0.15 (ethnic group unknown) 5 0.205 6
79 A4C Lys27Gln Reduced
8 or
unaltered
9 activity
0.04–0.108 7, 8 0.298–0.36 7, 8 0.201–0.207 6, 9
208 G4A Ala70Thr Reduced activity
9 0–0.13 7, 8 0 7, 8 0.037–0.043 6, 9
DCK (NT_006216.14)  360 C4G Increased mRNA
expression
11
0.02 10 0.156 11
 201 C4T 0.02 10 0.156 11
364 C4T Pro122Ser
d 0.015 10 0 11
727 A4C Lys243Gln
d 0.005 10 0 11
DCTD (NT_022792.17) 172 A4G Asn58Asp Reduced activity
8 0 8 0.008 8
315 T4C Val105Val 0.475–0.48 7, 8 0.25–0.333 7, 8
RRM1 (NT_009237.17)  524 T4C Different activity
among genotypes
12
0.277 12 0.361 12 0.360 12
 37 C4A 0.133 12 0.263 12 0.271 12
850 C4A
e Arg284Arg No different
mRNA expression
among genotypes
13
0.452 (cancer cell lines obtained from ATCC
f)1 3
2223 A4G
e Thr741Thr 0.597 (cancer cell lines obtained from ATCC
f)1 3
2232 G4A
e Ala744Ala 0.790 (cancer cell lines obtained from ATCC
f)1 3
aA of the translation initiation codon ATG is numbered 1.
bThe first methionine of a protein is numbered 1.
cOriginally reported as 1159 C4T.
dOriginally reported as
Pro121Ser and Lys242Gln.
eOriginally reported as 1082 C4A, 2455 A4G, and 2464 G4A.
fAmerican Type Culture Collection, Rockville, Maryland, USA. References:
1Myers
et al (2006),
2Kim et al (2006),
3Osato et al (2003),
4Damaraju et al (2005),
5Fitzgerald et al (2006),
6Sugiyama et al (2007),
7Fukunaga et al (2004),
8Gilbert et al (2006),
9Yue
et al (2003),
10Joerger et al (2006),
11Shi et al (2004),
12Bepler et al (2005),
13Kwon et al (2006).
9
> > =
> > ;
9
=
;
)
9
> > =
> > ;
)
Pharmacogenomics of gemcitabine
H Ueno et al
147
British Journal of Cancer (2007) 97(2), 145–151 & 2007 Cancer Research UKDEOXYCYTIDINE KINASE
Deoxycytidine kinase is the rate-limiting enzyme for the intra-
cellular phosphorylation of gemcitabine to its active phosphate
form. Therefore, DCK may play an important role in sensitivity to
gemcitabine. A clear correlation between DCK activity and
gemcitabine sensitivity in tumour xenografts has been reported
(Kroep et al, 2002).
Haplotype analysis in the 50 regulatory region ( 360C4G and
 201C4T) suggested that  360C/ 201C and  360G/ 201T had
almost complete linkage disequilibrium, and a functional study
revealed that patients carrying the  360CG/ 201CT and  360GG/
 201TT genotypes expressed significantly higher levels of DCK
mRNA than patients carrying the  360CC/ 201CC genotype (Shi
et al, 2004). Then the relationship between DCK SNP haplotypes
and event-free survival in 122 patients with acute myeloid
leukaemia treated with cytarabine was analysed, and slight but
statistically significant prolongation of event-free survival time in
the group with  360CG/ 201CT and  360GG/ 201TT over the
group with  360CC/ 201CC (2-year event-free survival rate, 30.7
vs 23.2%; P¼0.0423) was observed. Recently, Joerger et al (2006)
detected two nonsynonymous SNPs in a Caucasian population,
364C4T (Pro122Ser) and 727A4C (Lys243Gln), but their clinical
relevance has not yet been clarified.
Recent clinical studies have also shown an association between
tumoral DCK expression level and clinical outcome. Sebastiani
et al (2006) investigated the relationship between the clinical
outcome of pancreatic cancer patients treated with gemcitabine-
based chemotherapy and immunohistochemical expression of
DCK in cancer tissues. They reported that patients whose tumours
showed low DCK expression (n¼9) had significantly shorter
overall survival than those whose tumours showed high expression
(n¼23) (median, 14.6 vs 21.7 months; Po0.009). They also
sequenced the entire DCK-encoding gene in 17 human pancreatic
cancer cell lines and nine samples of cancer tissue from patients,
but no mutations were identified. Mey et al (2006) administered
gemcitabine intravesically to 12 patients with bladder cancer, and
reported that the mean expression of mRNA in the tumours was
significantly higher in patients who achieved a complete patholo-
gical response than in those who did not. On the other hand, Seve
et al (2005) reported that immunohistochemical expression of
DCK protein in tumours was not significantly correlated with the
survival of NSCLC patients treated with gemcitabine-based
chemotherapy.
50-NUCLEOTIDASE
Since phosphorylated metabolites of gemcitabine are reduced by
cellular 50-NT, the activity level of 50-NT may be one of the factors
affecting the clinical outcome of gemcitabine therapy. Using
malignant cells obtained from 43 NSCLC patients receiving
gemcitabine-based chemotherapy, Seve et al (2005) applied
immunohistochemical methods to assess the abundance of
proteins involved in gemcitabine pathways, including cN-II, one
of the cytosolic nucleotidases that have been shown to be
predictive factors in patients with acute myeloid leukaemia
(AML) receiving cytarabine. They reported that cN-II was
expressed in 86% of the patients, and that among various proteins
investigated, only the level of cN-II was significantly correlated
with overall survival (P¼0.02). Since low levels of cN-II were
associated with a poor prognosis in NSCLC patients receiving
gemcitabine and with a better prognosis in AML patients receiving
sytrabine (Seve et al, 2005), further studies are necessary to
confirm the usefulness of cN-II as a prognosis factor.
RIBONUCLEOTIDE REDUCTASE
Ribonucleotide reductase is the rate-limiting enzyme of the DNA
synthesis pathway and converts ribonucleoside diphosphate to
deoxyribonucleoside diphosphate, which is essential for DNA
synthesis and repair. Ribonucleotide reductase consists of two
Table 2 Pharmacokinetic parameters of gemcitabine in the patient
groups categorized according to diplotypes
Mean7s.d.
Diplotype *1/*1 (n¼148) *2/*1 (n¼69) *2/*2 (n¼15)
PK parameter P-value
a
Cmax (mgml
 1) 22.776.3 22.976.4 24.175.5 0.52
AUC (hmgml
 1) 10.172.5 9.872.3 9.871.5 0.46
CLm
 2 (lh
 1m
 2) 105.8731.1 107.2727.2 103.3719.2 0.99
Mean7s.d.
Diplotype *1/*1 (n¼148) *3/*1 (n¼13) *3/*3 (n¼1)
PK parameter P-value
a
Cmax (mgml
 1) 22.776.3 26.875.9 46.4 5.94E-04
AUC (hmgml
 1) 10.172.5 12.772.6 52.9 6.66E-13
CLm
 2 (lh
 1m
 2) 105.8731.1 82.6724.9 18.9 7.77E-04
aP-value of a correlation test. Multiplicity is adjusted by the false-discovery rate.
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Figure 2 Effects of CDA *3 on the pharmacokinetic parameters of
gemcitabine. (A) Area under the curve (AUC) and (B) clearance
(CLm
 2). Each point corresponds to an individual patient. The bars
denote the median values.
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reductase M2 (RRM2).
Kwon et al (2006) investigated the association between poly-
morphisms of RRM1 and gemcitabine chemosensitivity in vitro
using 62 human cancer cell lines. When the association between
these SNPs and gemcitabine IC50 was examined, only cell lines with
RRM1 2232G4A showed a tendency to be more chemosensitive to
gemcitabine, although none of the differences reached a statistically
significant level. Bepler et al (2005) analysed the RRM1 promoter for
polymorphism, and discovered two SNPs, RRM1  37C4Aa n d
 524T4C. There was a strong linkage between these SNPs, and
 37CC in combination with  524TT was the most frequently
observed allelotype, accounting for 42.4% of the ethnically diverse
population of 1129. They investigated RRM1 promoter allelotypes
and the outcomes of patients who had undergone surgical resection
for NSCLC. It was found that patients with the  37CC/ 524TT
allelotype had better overall and disease-free survival than patients
with the  37AC/ 524CT allelotype (median overall survival, 80 vs
46 months; P¼0.06, median disease-free survival, 74 vs 36 months;
P¼0.03). However, no association between allelotype and tumoral
RRM1 expression was found.
Rosell et al (2004b) examined the potential correlation of RRM1
mRNA expression in specimens of NSCLC resected from 67 patients
who had been treated with neoadjuvant gemcitabine/platinum. They
found a good correlation between RRM1 expression in tumours and
survival: significant differences in median survival were observed
between the 17 patients in the bottom quartile of RRM1 expression
and the 15 in the top quartile (median, 52 vs 26 months; P¼0.018).
They also reported similar results in patients with advanced
NSCLC treated with gemcitabine/cisplatin therapy (Rosell et al,
2004a). Patients with low RRM1 mRNA expression levels had
significantly longer median survival than those with high levels
(median, 13.7 vs 3.6 months; P¼0.009). Bepler et al (2006) also
reported that increased RRM1 expression resulted in resistance to
gemcitabine both in vitro and clinically. They found that the
gemcitabine IC50 of lung cancer cell lines with increased RRM1
expression was higher than that of cell lines with decreased RRM1
expression, and the results they obtained in a prospective phase II
clinical trial in patients with advanced NSCLC showed a significant
inverse correlation between RRM1 expression and disease response
to gemcitabine and carboplatin therapy (P¼0.002 and r¼ 0.498).
Therefore, tumoral RRM1 expression may be a useful marker
of outcome in NSCLC patients receiving gemcitabine-based
chemotherapy.
With regard to RRM2, the association between its genetic
polymorphisms and resistance to gemcitabine has not been
reported. Duxbury et al (2005) demonstrated an association of
RRM2 overexpression with gemcitabine chemoresistance in
pancreatic adenocarcinoma cells: the gemcitabine IC50 was four
times higher in RRM2 recombinant than with an empty vector
(Po0.05). Goan et al (1999) selected a gemcitabine-resistant cell
line KB-GEM (IC50¼32mM) from human oropharyngeal epider-
moid carcinoma KB cells (IC50¼0.3mM), and found that RRM2
mRNA (nine-fold) and protein (two-fold) were overexpressed in
KB-GEM in comparison with the parental KB cells.
DEOXYCYTIDYLATE DEAMINASE AND UMP/CMP
KINASE
Gemcitabine monophosphate is inactivated to dFdUMP by DCTD.
A few SNPs including a nonsynonymous one, DCTD 172A4G
(Asn58Asp), have been reported (Table 1; Fukunaga et al, 2004;
Gilbert et al, 2006). Recombinant Asp58 DCTD was reported to
have 11% of wild-type activity for dFdCMP. dFdCMP is further
phosphorylated to dFdCDP by UMP/CMP kinase, which is
ubiquitously present in human tissues (van Rompay et al, 1999).
To date, neither association of genetic polymorphisms nor
expression of either DCTD or UMP/CMP kinase with clinical
outcome of gemcitabine treatment has been demonstrated.
DNA REPAIR
As the main mechanism of action of gemcitabine is potent inhibition
of DNA synthesis, DNA repair may play an important role in
gemcitabine-mediated cell death. Recently, Li et al (2006) investi-
gated 13 SNPs of eight DNA damage response and repair genes in 92
patients with resectable pancreatic cancer treated with neoadjuvant
gemcitabine-based chemotherapy. They found that RecQ1 1596(*6),
Rad54L 2190C4T, and ATM IVS20-77 T4Cg e n o t y p e sh a da
significant effect on overall survival. The strongest genetic effect on
survival was observed for RecQ1 1596(*6), with median overall
survival times of 18.9 and 13.1 months for the AC and CC genotypes,
respectively, compared with a mean survival time of 46.9 months for
the AA wild type (P¼0.001). De las Penas et al (2006) investigated
the association of survival with genetic polymorphisms of various
DNA repair genes in 135 cisplatin/gemcitabine-treated NSCLC
patients at stage IIIB and IV. After adjusting for performance status,
a significantly low hazard ratio (0.44) for carriers of XRCC3 722TT
(241Met/Met) compared to carriers of 722CT (241Thr/Met) was
demonstrated (P¼0.01). With regard to the expression levels of
DNA repair genes, Lord et al (2002) investigated the relationship
between excision repair cross-complementing group 1 ERCC1
expression in tumours with response or overall survival in NSCLC
patients treated with cisplatin/gemcitabine. They failed to show any
significant association between ERCC1 expression and response, but
reported that low expression of ERCC1 in tumours was associated
with longer survival (61.6 vs 20.4 weeks in the low and high
expression groups, respectively). Bepler et al (2006) also found a
similar trend for the relationship between ERCC1 expression and
NSCLC response. Cytotoxic synergism has been demonstrated
between gemcitabine and cisplatin through downregulation of
E R C C 1a c t i v i t yb yg e m c i t a b i n e( L o r det al, 2002).
CONCLUSION AND FUTURE DIRECTIONS
In this article, we have reviewed recent genetic studies of
gemcitabine. The impact of genetic polymorphisms as well as
tumour-specific expression of mRNA/proteins on gemcitabine
efficacy and toxicity has been described. Looking at these data,
tumour-specific expression of ENT1, RRM1 or ERCC1, or some
DNA repair genetic polymorphisms appear to be promising
indicators of prognosis in patients receiving gemcitabine che-
motherapy, although prospective pharmacogenetic-based clinical
studies will be necessary to clarify the usefulness of these
biomarkers in patients receiving gemcitabine-based chemother-
apy. With regard to adverse reactions caused by gemcitabine, the
expression level or genetic polymorphism of CDA seems to be a
good predictor. SNP, CDA 208A4G, or CDA expression level may
be candidate biomarkers for individualised gemcitabine-based
chemotherapy to avoid severe toxicity, at least in Japanese and
some African populations in which considerable numbers of
homozygote carriers exist, as is the case for UGT1A1*28 for
irinotecan and TPMT genotypes for thiopurine drugs.
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